AAM
BIO icon

Ardevora Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Ardevora Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-92,340
Closed -$35M – 122
2023
Q2 		$35M Sell
92,340
-13,014
-12% -$5.3M 0.85% 55
2023
Q1 		$50.5M Sell
105,354
-8,793
-8% -$4.12M 0.91% 54
2022
Q4 		$48M Buy
114,147
+9,918
+10% +$4M 0.82% 44
2022
Q3 		$43.5M Sell
104,229
-7,719
-7% -$3.85M 0.78% 64
2022
Q2 		$55.4M Buy
111,948
+4,200
+4% +$2.19M 0.91% 34
2022
Q1 		$60.7M Buy
107,748
+3,358
+3% +$2.02M 0.79% 73
2021
Q4 		$78.9M Buy
104,390
+900
+0.9% +$674K 0.84% 36
2021
Q3 		$77.2M Sell
103,490
-15,000
-13% -$11.2M 0.98% 7
2021
Q2 		$76.3M Buy
118,490
+25,933
+28% +$15.8M 0.96% 12
2021
Q1 		$52.9M Sell
92,557
-3,100
-3% -$1.84M 0.79% 76
2020
Q4 		$55.8M Sell
95,657
-10,100
-10% -$5.75M 0.86% 71
2020
Q3 		$54.5M Buy
105,757
+900
+0.9% +$456K 1% 24
2020
Q2 		$47.3M Buy
+104,857
New +$46.3M 0.93% 39

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ardevora Asset Management's BIO Position: Q3 2023 in Review

Ardevora Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2023, closing a stake of 92,340 shares — an estimated $35M sold.

Ardevora Asset Management first reported a position in BIO in Q2 2020 and held it in 13 quarters. The position peaked at $78.9M in Q4 2021. 467 funds tracked by Wall St. Rank hold BIO as of Q3 2023.

  • Ardevora Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2023 after selling out during the quarter.
  • Ardevora Asset Management sold 92,340 Bio-Rad Laboratories Class A shares in Q3 2023, an estimated $35M.
  • Ardevora Asset Management first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and held it in 13 quarters.
  • Ardevora Asset Management's Bio-Rad Laboratories Class A position peaked at $78.9M in Q4 2021.
  • 467 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2023.

Based on Ardevora Asset Management's 13F filing for Q3 2023, filed 25 Oct 2023.